Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150 increases the chemosensitivity and decreases tumor initiating potential of neuroblastoma cells

被引：0
|
作者：
Odate, Seiichi
Yan, Shuang
Veschi, Veronica
Lam, Norris
Liu, Zhihui
Thiele, Carol J.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445,AM2016-2439
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2439
引用
收藏
页数：4
相关论文
共 18 条
  • [1] Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity
    Odate, Seiichi
    Veschi, Veronica
    Yan, Shuang
    Lam, Norris
    Woessner, Richard
    Thiele, Carol J.
    CLINICAL CANCER RESEARCH, 2017, 23 (07) : 1771 - 1784
  • [2] AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
    Hong, David
    Kurzrock, Razelle
    Kim, Youngsoo
    Woessner, Richard
    Younes, Anas
    Nemunaitis, John
    Fowler, Nathan
    Zhou, Tianyuan
    Schmidt, Joanna
    Jo, Minji
    Lee, Samantha J.
    Yamashita, Mason
    Hughes, Steven G.
    Fayad, Luis
    Piha-Paul, Sarina
    Nadella, Murali V. P.
    Mohseni, Morvarid
    Lawson, Deborah
    Reimer, Corinne
    Blakey, David C.
    Xiao, Xiaokun
    Hsu, Jeff
    Revenko, Alexey
    Monia, Brett P.
    MacLeod, A. Robert
    SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (314)
  • [3] Preclinical pharmacology and clinical efficacy of AZD9150 (ISIS-STAT3Rx), a potent next-generation antisense oligonucleotide inhibitor of STAT3
    Hong, David
    Kim, Youngsoo
    Younes, Anas
    Nemunaitis, John
    Fowler, Nathan
    Hsu, Jeff
    Zhou, Tianyuan
    Fayad, Luis
    Zhang, Nancy
    Piha-Paul, Sarina
    Woessner, Richard
    Nadella, Murali V.
    Lawson, Deborah
    Reimer, Corinne
    Jo, Minji
    Schmidt, Joanna
    Xiao, Xiaokun
    Greenlee, Sarah
    Hung, Gene
    Yamashita, Mason
    Blakey, David C.
    Monia, Brett P.
    Macleod, A. Robert
    Kurzrock, Razelle
    CANCER RESEARCH, 2014, 74 (19)
  • [4] STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
    Reilley, Matthew J.
    McCoon, Patricia
    Cook, Carl
    Lyne, Paul
    Kurzrock, Razelle
    Kim, Youngsoo
    Woessner, Richard
    Younes, Anas
    Nemunaitis, John
    Fowler, Nathan
    Curran, Michael
    Liu, Qinying
    Zhou, Tianyuan
    Schmidt, Joanna
    Jo, Minji
    Lee, Samantha J.
    Yamashita, Mason
    Hughes, Steven G.
    Fayad, Luis
    Piha-Paul, Sarina
    Nadella, Murali V. P.
    Xiao, Xiaokun
    Hsu, Jeff
    Revenko, Alexey
    Monia, Brett P.
    MacLeod, A. Robert
    Hong, David S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [5] Potent in vivo pharmacology of AZD9150, a next-generation, constrained ethyl-modified antisense oligonucleotide targeting STAT3 in multiple preclinical cancer models.
    Kim, Youngsoo
    Hsu, Jeff
    Zhou, Tianyuan
    Zhang, Nancy
    Woessner, Richard
    Nadella, Murali V. P.
    Lawson, Deborah
    Reimer, Corinne
    He, Guobin
    Schmidt, Joanna
    Xiao, Xiaokun
    Greenlee, Sarah
    Bhattacharjee, Gourab
    Hung, Gene
    Monia, Brett P.
    MacLeod, A. Robert
    CANCER RESEARCH, 2013, 73 (08)
  • [6] A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers
    Hong, David S.
    Younes, Anas
    Fayad, Luis
    Fowler, Nathan Hale
    Hagemeister, Fredrick B.
    Mistry, Reena
    Nemunaitis, John J.
    Borad, Mitesh J.
    Bryce, Alan H.
    Yamashita, Mason
    Hughes, Steven George
    Kwoh, Theodore Jesse
    MacLeod, A. Robert
    Norris, Dan
    Baldwin, Ron
    Hung, Gene
    Monia, Brett P.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Targeting MDS and AML Stem Cells with AZD-9150 Mediated Inhibition of STAT3
    Shastri, Aditi
    Teixeira, Margarida
    Bhattacharyya, Sanchari
    Ramachandra, Nandini
    Lopez, Robert
    Ravipati, Goutham
    Feld, Jonathan
    Dhar, Yosman
    Bhagat, Tushar Damodar
    Choudhary, Gaurav
    Giricz, Orsolya
    Bartenstein, Matthias
    Sridharan, Ashwin
    Gordon-Mitchell, Shanisha
    Nawanko, George
    Pradhan, Kith
    Ahmed, Amal
    Raghavendran, Keshav
    Kanna, Rubashruti
    Khan, Hina
    Mantzaris, Ioannis
    Pellagatti, Andrea
    Boultwood, Jacqueline
    Kim, Youngsoo
    McLeod, Robert
    Woessner, Richard
    Steidl, Ulrich
    Will, Britta
    Verma, Amit
    BLOOD, 2016, 128 (22)
  • [8] Inhibition of STAT3 by antisense oligonucleotide treatment decreases the immune suppressive tumor microenvironment in syngeneic and GEM tumor models
    Woessner, Rich
    Sah, Vasu
    McCoon, Patricia
    Grosskurth, Shaun
    Deng, Nanhua
    DuPont, Rachel
    Lawson, Deborah
    Pablo, Lourdes
    Reimer, Corinne
    De Velasco, Marco A.
    Uemura, Hirotsugu
    Candido, Juliana
    Lyne, Paul
    CANCER RESEARCH, 2017, 77
  • [9] Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo
    Yan, Shuang
    Li, Zhijie
    Thiele, Carol J.
    ONCOTARGET, 2013, 4 (03) : 433 - 445
  • [10] Immunological STAT3 knockdown associated with anti-tumor activity in pre-clinical models translates to clinical samples, suggesting immune modulation contributes to the clinical activity of AZD9150, a therapeutic STAT3 ASO
    McCoon, P.
    Woessner, R.
    DuPont, R.
    Bell, K.
    Collins, M.
    Pablo, L.
    Lawson, D.
    Nadella, P.
    Jacobs, V.
    Womack, C.
    Reimer, C.
    Hong, D.
    Nemunaitis, J.
    Kang, Y. K.
    Kim, T. Y.
    Lim, H. Y.
    Okusaka, T.
    Nadano, S.
    Lin, C. C.
    Lyne, P.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 163 - 164
12